Logo image of PIRS

PIERIS PHARMACEUTICALS INC (PIRS) Stock Fundamental Analysis

NASDAQ:PIRS - Nasdaq - US7207952026 - Common Stock - Currency: USD

13.6  -2.53 (-15.69%)

After market: 13.26 -0.34 (-2.5%)

Fundamental Rating

3

Taking everything into account, PIRS scores 3 out of 10 in our fundamental rating. PIRS was compared to 558 industry peers in the Biotechnology industry. PIRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, PIRS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PIRS has reported negative net income.
PIRS had a negative operating cash flow in the past year.
In the past 5 years PIRS always reported negative net income.
PIRS had a negative operating cash flow in each of the past 5 years.
PIRS Yearly Net Income VS EBIT VS OCF VS FCFPIRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

1.2 Ratios

With a Return On Assets value of -77.74%, PIRS is not doing good in the industry: 68.85% of the companies in the same industry are doing better.
The Return On Equity of PIRS (-98.06%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROIC N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
PIRS Yearly ROA, ROE, ROICPIRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PIRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PIRS Yearly Profit, Operating, Gross MarginsPIRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

PIRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PIRS has been increased compared to 1 year ago.
PIRS has more shares outstanding than it did 5 years ago.
PIRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PIRS Yearly Shares OutstandingPIRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
PIRS Yearly Total Debt VS Total AssetsPIRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.87, we must say that PIRS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PIRS (-8.87) is worse than 71.50% of its industry peers.
PIRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.87
ROIC/WACCN/A
WACC11.91%
PIRS Yearly LT Debt VS Equity VS FCFPIRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

PIRS has a Current Ratio of 4.82. This indicates that PIRS is financially healthy and has no problem in meeting its short term obligations.
PIRS has a Current ratio (4.82) which is comparable to the rest of the industry.
PIRS has a Quick Ratio of 4.82. This indicates that PIRS is financially healthy and has no problem in meeting its short term obligations.
PIRS's Quick ratio of 4.82 is in line compared to the rest of the industry. PIRS outperforms 54.69% of its industry peers.
Industry RankSector Rank
Current Ratio 4.82
Quick Ratio 4.82
PIRS Yearly Current Assets VS Current LiabilitesPIRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.86% over the past year.
The Revenue for PIRS has decreased by -97.15% in the past year. This is quite bad
The Revenue has been growing by 8.03% on average over the past years. This is quite good.
EPS 1Y (TTM)54.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.86%
Revenue 1Y (TTM)-97.15%
Revenue growth 3Y13.44%
Revenue growth 5Y8.03%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 3.67% on average over the next years.
PIRS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.76% yearly.
EPS Next Y42.86%
EPS Next 2Y8.23%
EPS Next 3Y3.67%
EPS Next 5YN/A
Revenue Next Year-79.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.76%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PIRS Yearly Revenue VS EstimatesPIRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 2028 2029 2030 50M 100M 150M 200M
PIRS Yearly EPS VS EstimatesPIRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PIRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PIRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PIRS Price Earnings VS Forward Price EarningsPIRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PIRS Per share dataPIRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.23%
EPS Next 3Y3.67%

More info and screens

0

5. Dividend

5.1 Amount

PIRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PIERIS PHARMACEUTICALS INC

NASDAQ:PIRS (12/13/2024, 8:00:01 PM)

After market: 13.26 -0.34 (-2.5%)

13.6

-2.53 (-15.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners47.71%
Inst Owner Change-78.57%
Ins Owners0.07%
Ins Owner Change0%
Market Cap108.39M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-85.23%
Min Revenue beat(4)-100%
Max Revenue beat(4)-43.25%
Revenue beat(8)2
Avg Revenue beat(8)14.08%
Revenue beat(12)4
Avg Revenue beat(12)34.44%
Revenue beat(16)6
Avg Revenue beat(16)33.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80.17
P/FCF N/A
P/OCF N/A
P/B 6.66
P/tB 6.66
EV/EBITDA N/A
EPS(TTM)-12.61
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-3.51
FCFYN/A
OCF(TTM)-3.51
OCFYN/A
SpS0.17
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.68%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.82
Quick Ratio 4.82
Altman-Z -8.87
F-Score2
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)28.39%
Cap/Depr(5y)118.53%
Cap/Sales(3y)2.48%
Cap/Sales(5y)4.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.86%
EPS Next Y42.86%
EPS Next 2Y8.23%
EPS Next 3Y3.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.15%
Revenue growth 3Y13.44%
Revenue growth 5Y8.03%
Sales Q2Q%-100%
Revenue Next Year-79.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.76%
EBIT growth 1Y17.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.68%
OCF growth 3YN/A
OCF growth 5YN/A